Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2026-02-11T13:59:37.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    A government funding lapse notice about site status has been added, and the page version was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:15:24.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    Minor metadata and UI label updates were applied, including changes to update date labels (Last Update Submitted that Met QC Criteria and Last Update Posted), No FEAR Act labeling, a new Revision: v3.4.0, and the addition of a 'Show glossary' option. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2026-01-28T05:13:39.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision indicator updated from v3.3.3 to v3.3.4. No changes to the study information or page layout are evident.
    Difference
    0.1%
    Check dated 2026-01-14T02:08:47.000Z thumbnail image
  6. Check
    63 days ago
    Change Detected
    Summary
    Locations now list California, District of Columbia, Florida, Michigan, and Tennessee. The HHS Vulnerability Disclosure link was removed and the page revision updated to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-23T20:41:47.000Z thumbnail image
  7. Check
    91 days ago
    Change Detected
    Summary
    Revision updated from v3.2.0 to v3.3.2 on the study page; no substantive content changes to the study details or eligibility criteria are evident. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-25T13:59:42.000Z thumbnail image

Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.